Abstract: Enzymes are biocatalysts evolved in nature to achieve the speed and coordination of nearly all the chemical reactions that define cellular metabolism necessary to develop and maintain life. The application of biocatalysis is growing rapidly, since enzymes offer potential for many exciting applications in industry. The advent of whole genome sequencing projects enabled new approaches for biocatalyst development, based on specialised methods for enzyme heterologous expression and engineering. The engineering of enzymes with altered activity, specificity and stability, using sitedirected mutagenesis and directed evolution techniques are now well established. Over the last decade, enzyme immobilisation has become important in industry. New methods and techniques for enzyme immobilisation allow for the reuse of the catalysts and the development of efficient biotechnological processes. This chapter reviews advances in enzyme technology as well as in the techniques and strategies used for enzyme production, engineering and immobilisation and discuss their advantages and disadvantages.
PREFACE
Enzymes are proteins with powerful catalytic functions. They increase reaction rates sometimes by as much as one million fold, but more typically by about one thousand fold. Catalytic activity can also be shown, to a limited extent, by biological molecules other than the 'classical' enzymes. For example, antibodies raised to stable analogues of the transition states of a number of enzyme-catalysed reactions can act as effective catalysts for those reactions (Hsieh-Wilson et al. 1996) . In addition, RNA molecules can also act as a catalyst for a number of different types of reactions (Lewin 1982) . These antibodies and RNA catalysts are known as abzymes and ribozymes, respectively.
Enzymes have a number of distinct advantages over conventional chemical catalysts. Among these are their high productivity, catalytic efficiency, specificity and their ability to discriminate between similar parts of molecules (regiospecificity) or optical isomers (stereospecificity). Enzymes, in general, work under mild conditions of temperature, pressure and pH. This advantage decreases the energy requirements and therefore reduces the capital costs. However, there are some disadvantages in the use of enzymes, such as high cost and low stability. These shortcomings are currently being addressed mainly by employing protein engineering approaches using recombinant DNA technology (Stemmer 1994, Ke and Madison 1997) . These approaches aim at improving various properties such as thermostability, specificity and catalytic efficiency. The advent of designer biocatalysts enables production of not only process-compatible enzymes, but also novel enzymes able to catalyse new or unexploited reactions (Schmidt-Dannert et al. 2000, Umeno and Arnold 2004) . This is just the start of the enzyme technology era.
ENZYME STRUCTURE AND MECHANISM

Nomenclature and Classification of Enzymes
Enzymes are classified according to the nature of the reaction they catalyse (e.g. oxidation/reduction, hydrolysis, synthesis, etc.) and sub-classified according to the exact identity of their substrates and products. This nomenclature system was established by the Enzyme Commission (a committee of the International Union of Biochemistry). According to this system, all enzymes are classified into six major classes:
1. Oxidoreductases, which catalyse oxidation-reduction reactions. 2. Transferases, which catalyse group transfer from one molecule to another. 3. Hydrolases, which catalyse hydrolytic cleavage of C-C, C-N, C-O, C-S or O-P bonds. These are group transfer reactions but the acceptor is always water. 4. Lyases, which catalyse elimination reactions, resulting in the cleavage of C-C, C-O, C-N, C-S bonds or the formation of a double bond, or conversely adding groups to double bonds. 5. Isomerases, which catalyse isomerisation reactions, e.g., racemisation, epimerisation, cis-trans-isomerisation, tautomerisation. 6. Ligases, which catalyse bond formation, coupled with the hydrolysis of a high-energy phosphate bond in ATP or a similar triphosphate.
The Enzyme Commission system consists of a numerical classification hierarchy of the form 'E.C. a.b.c.d' in which 'a' represents the class of reaction catalysed and can take values from 1 to 6 according to the classification of reaction types given above. 'b' denotes the sub-class, which usually specifies more precisely the type of the substrate or the bond cleaved, e.g. by naming the electron donor of an oxidation-reduction reaction or by naming the functional group cleaved by a hydrolytic enzyme. 'c' denotes the sub-subclass, which allows an even more precise definition of the reaction catalysed. For example, sub-subclasses of oxidoreductases are denoted by naming the acceptor of the electron from its respective donor. 'd' is the serial number of the enzyme within its sub-subclass. An example will be analysed. The enzyme that oxidises d-glucose using molecular oxygen catalyses the following reaction: Hence, its systematic name is d-glucose: oxygen oxidoreductase, and its systematic number is EC 1.1.3.4.
The systematic names are often quite long, and therefore, short trivial names along with systematic numbers are often more convenient for enzyme designation. These shorter names are known as recommended names. The recommended names consist of the suffix '-ase' added to the substrate acted on. For example for the enzyme mentioned above, the recommended name is glucose oxidase.
It should be noted that the system of nomenclature and classification of enzymes is based only on the reaction catalysed and takes no account of the origin of the enzyme, that is from the species or tissue it derives.
Basic Elements of Enzyme Structure
The Primary Structure of Enzyme
Enzymes are composed of l-α-amino acids joined together by a peptide bond between the carboxylic acid group of one amino acid and the amino group of the next. There are 20 common amino acids in proteins, which are specified by the genetic code; in rare cases, others occur as the products of enzymatic modifications after translation. A common feature of all 20 amino acids is a central carbon atom (C α ) to which a hydrogen atom, an amino group (-NH 2 ) and a carboxy group (-COOH) are attached. Free amino acids are usually zwitterionic at neutral pH, with the carboxyl group deprotonated and the amino group protonated. The structure of the most common amino acids found in proteins is shown in Table 7 .1. Amino acids can be divided into four different classes depending on the structure of their side chains, which are called R groups: nonpolar, polar uncharged, negatively charged (at neutral pH) and positively charged (at neutral pH; Richardson 1981) . The properties of the amino acid side chains determine the properties of the proteins they constitute. The formation of a succession of peptide bonds generates the 'main chain' or 'backbone'.
The primary structure of a protein places several constrains on how it can fold to produce its three-dimensional structure (Cantor 1980 , Fersht 1999 . The backbone of a protein consists of a carbon atom C α to which the side chain is attached, a NH group bound to C α and a carbonyl group C = O, where the carbon atom C is attached to C α ( Fig. 7. 1) The peptide bond is planar since it has partial (∼40%) double bond character with π electrons shared between the C-O and C-N bonds ( Fig. 7 .1). The peptide bond has a trans-conformation, that is the oxygen of the carbonyl group and the hydrogen of the NH group are in the trans position; the cis conformation occurs only in exceptional cases (Richardson 1981) .
Enzymes have several 'levels' of structure. The protein's sequence, that is the order of amino acids, is termed as its 'primary structure'. This is determined by the sequence of nucleotide bases in the gene that codes for the protein. Translation of the mRNA transcript produces a linear chain of amino acids linked together by a peptide bond between the carboxyl carbon of the first amino acid and the free amino group of the second amino acid. The first amino acid in any polypeptide sequence has a free amino group and the terminal amino acid has a free carboxyl group. The primary structure is responsible for the higher levels of enzyme's structure and therefore for the enzymatic activity (Richardson 1981, Price and Stevens 1999) .
The Three-Dimensional Structure of Enzymes
Enzymes are generally very closely packed globular structures with only a small number of internal cavities, which are normally filled by water molecules. The polypeptide chains of enzymes are organised into ordered, hydrogen bonded regions, known as secondary structure (Andersen and Rost 2003) . In these ordered structures, any buried carbonyl oxygen forms a hydrogen bond with an amino NH group. This is done by forming α-helices and β-pleated sheets, as shown in Figure 7 .2. The α-helix can be thought of as having a structure similar to a coil or spring (Surewicz and Mantsch 1988) . The β-sheet can be visualised as a series of parallel strings laid on top of an accordionfolded piece of paper. These structures are determined by the protein's primary structure. Relatively small, uncharged, polar amino acids readily organise themselves into α-helices, while relatively small, non-polar amino acids form β-sheets. Proline is a special amino acid because of its unique structure (Table 7 .1). Introduction of proline into the sequence creates a permanent bend at that position (Garnier et al. 1990 ). Therefore, the presence of proline in an α-helix or β-sheet disrupts the secondary structure at that point. The presence of a glycine residue confers greater than normal flexibility on a polypeptide chain. This is due to the absence of a bulky side chain, which reduces steric hindrance.
Another frequently observed structural unit is the β-turn (Fang and Shortle 2003) . This occurs when the main chain sharply changes direction using a bend composed of four successive residues, often including proline and glycine. In these units, the C = O group of residue i is hydrogen bonded to the NH of residue i+3 instead of i+4 as in α-helix. Many different types of β-turn have been identified, which differ in terms of the number of amino acids and in conformation (e.g. Type I, Type II, Type III; Sibanda et al. 1989) .
The three-dimensional structure of a protein composed of a single polypeptide chain is known as its tertiary structure. Tertiary structure is determined largely by the interaction of R groups on the surface of the protein with water and with other R groups on the protein's surface. The intermolecular noncovalent attractive forces that are involved in stabilising the enzyme's structure are usually classified into three types: ionic bonds, hydrogen bonds and van der Waals attractions (Matthews 1993) . Hydrogen bonding results from the formation of hydrogen bridges between appropriate atoms; electrostatic bonds are due to the attraction of oppositely charged groups located on two amino acid side chains. Van der Waals bonds are generated by the interaction between electron clouds. Another important weak force is created by the three-dimensional structure of water, which tends to force hydrophobic groups together in order to minimise their disruptive effect on hydrogen-bonded network of water molecules. Apart from the peptide bond, the only other type of covalent bond involved in linking aminoacids is the disulphide (-S-S-) bond, which can be formed between two cysteine side-chains under oxidising conditions. The disulphide bond contributes significantly to the structural stability of an enzyme and more precisely in tertiary structural stabilisation (see below for details; Matthews 1993 , Estape et al. 1998 .
Detailed studies have shown that certain combinations of α-helices or β-sheet together with turns occur in many proteins. These often-occurring structures have been termed motifs, or super-secondary structure (Kabsch and Sander 1983, Adamson et al. 1993) . Examples of motifs found in several enzymes are shown in Figure 7 .3. These protein folds represent highly stable structural units, and it is believed that they may form nucleating centres in protein folding (Richardson 1981) . Certain combinations of α-helices and β-sheets pack together to form compactly folded globular units, each of which is called protein domain with molecular mass of 15,000 to 20,000 Da (Orengo et al. 1997) . Domains may be composed of secondary structure and identifiable motifs and therefore represent a higher level of structure than motifs. The most widely used classification scheme of domains has been the four-class system ( Fig. 7.4 ; Murzin et al. 1995) . The four classes of protein structure are as follows:
1. All-α-proteins, which have only α-helix structure. 2. All-β-proteins, which have β-sheet structure. 3. α/β-proteins, which have mixed or alternating segments of α-helix and β-sheet structure. 4. α+β proteins, which have α-helix and β-sheet structural segments that do not mix but are separated along the polypeptide chain.
While small proteins may contain only a single domain, larger enzymes contain a number of domains. In fact, most enzymes are dimers, tetramers or polymers of several polypeptide chains. Each polypeptide chain is termed 'subunit' and it may be identical or different to the others. The side chains on each polypeptide chain may interact with each other, as well as with water molecules to give the final enzyme structure. The overall organisation of the subunits is known as the quaternary structure and therefore the quaternary structure is a characteristic of multi-subunit enzymes. The four levels of enzyme structure are illustrated in Figure 7 .5.
Theory of Enzyme Catalysis and Mechanism
In order for a reaction to occur, the reactant molecules must possess sufficient energy to cross a potential energy barrier, which is known as the activation energy (Fig. 7.6; Hackney 1990 ). All reactant molecules have different amounts of energy, but only a small proportion of them have sufficient energy to cross the activation energy of the reaction. The lower the activation energy, the more substrate molecules are able to cross the activation energy. The result is that the reaction rate is increased.
Enzyme catalysis requires the formation of a specific reversible complex between the substrate and the enzyme. This complex is known as the enzyme-substrate complex (ES) and provides all the conditions that favour the catalytic event (Hackney 1990, Marti et al. 2004 ). Enzymes accelerate reactions by lowering the energy required for the formation of a complex of reactants that is competent to produce reaction products. This complex is known as the transition state complex of the reaction and is characterised by lower free energy than it would be found in the uncatalysed reaction. The ES must pass to the transition state (ES*). The transition state complex must advance to an enzyme-product complex (EP), which dissociates to free enzyme and product (P). This reaction's pathway goes through the transition states TS 1 , TS 2 and TS 3 . The amount of energy required to achieve the transition state is lowered; hence, a greater proportion of the molecules in the population can achieve the transition state and cross the activation energy Hammes-Schiffer 2003, Wolfenden 2003) . Enzymes speed up the forward and reverse reactions proportionately, so that they have no effect on the equilibrium constant of the reactions they catalyse (Hackney 1990) .
Substrate is bound to the enzyme by relatively weak noncovalent forces. The free energy of interaction of the ES complex ranges between −12 to −36 kJ/mole. The intermolecular attractive forces between enzyme-substrate, in general, are of three types: ionic bonds, hydrogen bonds and van der Waals attractions.
Specific part of the protein structure that interacts with the substrate is known as the substrate binding site (Fig. 7.7 ). The substrate binding site is a three-dimensional entity suitably designed as a pocket or a cleft to accept the structure of the substrate in three-dimensional terms. The binding residues are defined as any residue with any atom within 4 Å of a bound substrate. These binding residues that participate in the catalytic event are known as the catalytic-residues and form the active-site. According to Bartlett et al. (Bartlett et al. 2002) , a residue is defined as catalytic if any of the following take place:
1. Direct involvement in the catalytic mechanism, for example as a nucleophile. 2. Exerting an effect, that aids catalysis, on another residue or water molecule, which is directly involved in the catalytic mechanism. 3. Stabilisation of a proposed transition-state intermediate. 4. Exerting an effect on a substrate or cofactor that aids catalysis, for example by polarising a bond that is to be broken. Despite the impression that the enzyme's structure is static and locked into a single conformation, several motions and conformational changes of the various regions always occur (Hammes 2002) . The extent of these motions depends on many factors, including temperature, the properties of the solvating medium, the presence or absence of substrate and product (Hammes 2002) . The conformational changes undergone by the enzyme play an important role in controlling the catalytic cycle. In some enzymes, there are significant movements of the binding residues, usually on surface loops, and in other cases, there are larger conformational changes. Catalysis takes place in the closed form and the enzyme opens again to release the product. This favoured model that explains enzyme catalysis and substrate interaction is the so-called induced fit hypothesis (Anderson et al. 1979 , Joseph et al. 1990 . In this hypothesis, the initial interaction between enzyme and substrate rapidly induces conformational changes in the shape of the active site, which results in a new shape of the active site that brings catalytic residues close to substrate bonds to be altered ( Fig. 7.8 ). When binding of the substrate to the enzyme takes place, the shape adjustment triggers catalysis by generating transition-state complexes. This hypothesis helps to explain why enzymes only catalyse specific reactions (Anderson et al. 1979 , Joseph et al. 1990 ). This basic cycle has been seen in many different enzymes, including triosephosphate isomerase, which uses a small hinged loop to close the active site (Joseph et al. 1990 ) and kinases, which use two large lobes moving towards each other when the substrate binds (Anderson et al. 1979 ). 
Coenzymes, Prosthetic Groups and Metal Ion Cofactors
Non-protein groups can also be used by enzymes to affect catalysis. These groups, called cofactors, can be organic or inorganic and are divided into three classes: coenzymes, prosthetic groups and metal ion cofactors (McCormick 1975) . Prosthetic groups are tightly bound to an enzyme through covalent bond. Coenzymes bind to enzyme reversibly and associate and dissociate from the enzyme during each catalytic cycle and therefore may be considered as co-substrates. An enzyme containing a cofactor or prosthetic group is termed as holoenzyme. Coenzymes can be broadly classified into three main groups: coenzymes that transfer groups onto substrate, coenzymes that accept and donate electrons and compounds that activate substrates ( (Anderson et al. 1979) . In other cases, metals may form part of a prosthetic group in which they are bound by coordinate bonds (e.g. heme; Table 7 .2) in addition to side-chain groups. Usually, in this case, metal ions participate in electron transfer reactions.
Kinetics of Enzyme-Catalysed Reactions
The term enzyme kinetics implies a study of the velocity of an enzyme-catalysed reaction and of the various factors that may affect this (Moss 1988 ). An extensive discussion of enzyme kinetics would stay too far from the central theme of this chapter, but some general aspects will be briefly considered.
The concepts underlying the analysis of enzyme kinetics continue to provide significant information for understanding in vivo function and metabolism and for the development and clinical use of drugs aimed at selectively altering rate constants and interfering with the progress of disease states (Bauer et al. 2001) . Central scope of any study of enzyme kinetics is knowledge of the way in which reaction velocity is altered by changes in the concentration of the enzyme's substrate and of the simple mathematics underlying this (Wharton 1983 , Moss 1988 , Watson and Dive 1994 . As we have already discussed, the enzymatic reactions proceed through an intermediate ES in which each molecule of enzyme is combined, at any given instant during the reaction, with one substrate molecule. The reaction between enzyme and substrate to form the ES is reversible. Therefore, the overall enzymatic reaction can be shown as
where k +1 , k −1 and k +2 are the respective rate constants. The reverse reaction concerning the conversion of product to substrate is not included in this scheme. This is allowed at the beginning of the reaction when there is no, or little, product present. In 1913, biochemists Michaelis and Menten suggested that if the reverse reaction between E and S is sufficiently rapid, in comparison with the breakdown of ES complex to form product, the latter reaction will have a negligible effect on the concentration of the ES complex. Consequently, E, S and ES will be in equilibrium, and the rates of formation and breakdown of ES will be equal. On the basis of these assumptions Michaelis and Menten produced the following equation:
This equation is a quantitative description of the relationship between the rate of an enzyme-catalysed reaction (u) and the concentration of substrate [S] . The parameters V max and K m are constants at a given temperature and a given enzyme concentration. The K m or Michaelis constant is the substrate concentration at which v = V max /2 and its usual unit is M. The K m provides us with information about the substrate binding affinity of the enzyme. A high K m indicates a low affinity and vice versa (Moss 1988, Price and Stevens 1999) .
The V max is the maximum rate of the enzyme-catalysed reaction and it is observed at very high substrate concentrations where all the enzyme molecules are saturated with substrate, in the form of ES complex. Therefore
where [E t ] is the total enzyme concentration and k cat is the rate of breakdown of the ES complex (k +2 in the equation), which is known as the turnover number. k cat represents the maximum number of substrate molecules that the enzyme can convert to product in a set time. The K m depends on the particular enzyme and substrate being used and on the temperature, pH, ionic strength, etc. However, note that K m is independent of the enzyme concentration, whereas V max is proportional to enzyme concentration. A plot of the initial rate (v) against initial substrate concentration ([S]) for a reaction obeying the Michaelis-Menten kinetics has the form of a rectangular hyperbola through the origin with asymptotes v = V max and [S] = −K m (Fig. 7.9A ). The term hyperbolic kinetics is also sometimes used to characterise such kinetics.
There are several available methods for determining the parameters from the Michaelis-Menten equation. A better method for determining the values of V max and K m was formulated by Hans Lineweaver and Dean Burk and is termed the LineweaverBurk (LB) or double reciprocal plot (Fig. 7.9B ). Specifically, it is a plot of 1/v versus 1/[S], according to the equation:
Such a plot yields a straight line with a slope of K m /V max . The intercept on the 1/v axis is 1/V max and the intercept on the 1/[S] axis is −1/K m .
The rate of an enzymatic reaction is also affected by changes in pH and temperature ( Fig. 7.10 ). When pH is varied, the velocity of reaction in the presence of a constant amount of enzyme is typically greatest over a relatively narrow range of pH. Since enzymes are proteins, they possess a large number of ionic groups, which are capable of existing in different ionic forms (Labrou et al. 2004a) . The existence of a fairly narrow pH-optimum for most enzymes suggests that one particular ionic form of the enzyme molecule, out of the many that it can potentially exist, is the catalytically active one. The effect of pH changes on v is reversible, except after exposure to extremes of pH at which denaturation of the enzyme may occur.
The rate of an enzymatic reaction increases with increasing temperature. Although there are significant variations from one enzyme to another, on average, for each 10
• C rise in temperature, the enzymatic activity is increased by an order of two. After exposure of the enzyme to high temperatures (normally greater that 65
• C), denaturation of the enzyme may occur and the enzyme activity decreased. The Arrhenius equation
+ A provides a quantitative description of the relationship between the rate of an enzyme-catalysed reaction (V max ) and the temperature (T). Where E a is the activation energy of the reaction, R is the gas constant, and A is a constant relevant to the nature of the reactant molecules. The rates of enzymatic reactions are affected by changes in the concentrations of compounds other than the substrate. These modifiers may be activators, that is they increase the rate of reaction or their presence may inhibit the enzyme's activity. Activators and inhibitors are usually small molecules or even ions. Enzyme inhibitors fall into two broad classes: those causing irreversible inactivation of enzymes and those whose inhibitory effects can be reversed. Inhibitors of the first class bind covalently to the enzyme so that physical methods of separating the two are ineffective. Reversible inhibition is characterised by the existence of equilibrium between enzyme and inhibitor (I):
The equilibrium constant of the reaction, K i , is given by the equation:
K i is a measure of the affinity of the inhibitor for the enzyme. Reversible inhibitors can be divided into three main categories: competitive inhibitors, non-competitive inhibitors and uncompetitive inhibitors. The characteristic of each type of inhibition and their effect on the kinetic parameters K m and V max are shown in Table 7 .3.
Thermodynamic Analysis
Thermodynamics is the science that deals with energy. Chemical bonds store energy, as the subatomic particles are being attracted and chemical reactions are occurred with energy changes. Originally, thermodynamic laws were used to analyse and characterise mechanical systems, but the kinetic molecular theory ( Eblin 1964) suggests that molecules are in constant motion, which obey the same laws of mechanics as macroscopic objects. Since enzymes are biomolecules, which catalyse chemical reactions, they contribute to the energetic background of a chemical system. As a result, enzymes are directly related to thermodynamic parameters.
In this section, we will focus on the most representative thermodynamic parameters that are useful, in order to describe experimental data. The fundamental thermodynamic parameters are the Helmholtz free energy (F), the entropy (S) and the enthalpy (H). Free energy (F) correlates the energy (E) of a system with its entropy (S): F = E − TS, where T is the temperature. The entropy (S) of a system is the range of its disorder and the thermodynamic definition is (Rakintzis 1994 ) (the symbol q is used to represent the amount of heat absorbed by a system):
Furthermore, enthalpy is a constitutive function of pressure (P) and temperature (T), and energy (E) is a constitutive func- tion of volume (V) and temperature (T), respectively (Rakintzis 1994) :
At this point, we have to emphasise that in biological systems, a normal experiment deals with a constant pressure (atmospheric pressure) and not with a constant volume. This means, that we determine not a change of energy (E) of a studied body (e.g. enzyme), but a change in its enthalpy: H = E + PV. However, the quantity (PV) is considered insignificant in case that we study a protein for instance, because the volume per molecule is too small. Hence, there is no difference between H and E, and we can refer both of them simply as "energy' (Finkelstein and Ptitsyn 2002) . Likewise, there is no difference between Helmholtz free energy (F = E − TS) and Gibb's free energy (G = H − TS), since we consider that H is equivalent to E. As a result, we 
Non-competitive Inhibitor The inhibitor binds to E or to the ES complex (may form an ESI complex) at a site other than the catalytic. Substrate binding is unchanged, whereas ESI complex cannot form products.
Uncompetitive Inhibitor Binds only to ES complexes at a site other than the catalytic site. Substrate binding alters enzyme structure, making inhibitor-binding site available:
can refer both F and G as 'free energy' (Finkelstein and Ptitsyn 2002) . Eventually, when we study the thermodynamic behaviour of an enzyme, regarding its structural stability or its functionality, we have to do with Gibb's free energy (G), entropy (S) and enthalpy (H). As far as experimental procedures are concerned, someone can use two equations in order to measure the thermodynamic parameters, applying temperature differentiation experimental protocols (Kotzia and Labrou 2005 
Eyring's equation is formed:
where k is the reaction velocity, R is the universal gas constant (8.3145
, h is the Plank constant (6.626 · 10 −34 J · s) and T is the absolute temperature in degrees Kelvin (K). If we compare Eyring's equation and Arrhenius equation (Laidler 1984) , we can realise that E and H are parallel quantities, as we concluded above. Eyring's equation is an appropriate and useful tool, which allows us to simplify the complicated meaning of thermodynamics and, simultaneously, to interpret experimental data to physical meanings.
Enzyme Dynamics During Catalysis
Multiple conformational changes and intramolecular motions appear to be a general feature of enzymes (Agarwal et al. 2002) . The structures of proteins and other biomolecules are largely maintained by non-covalent forces and are therefore subject to thermal fluctuations ranging from local atomic displacements to complete unfolding. These changes are intimately connected to enzymatic catalysis and are believed to fulfil a number of roles in catalysis: enhanced binding of substrate, correct orientation of catalytic groups, removal of water from the active site and trapping of intermediates. Enzyme conformational changes may be classified into four types (Gutteridge and Thornton 2004) : (i) domain motion, where two rigid domains, joined by a flexible hinge, move relative to each other; (ii) loop motion, where flexible surface loops (2-10 residues) adopt different conformations; (iii) side chain rotation, which alters the position of the functional atoms of the side chain and (iv) secondary structure changes.
Intramolecular motions in biomolecules are usually very fast (picosecond-nanosecond) local fluctuations. The flexibility associated with such motions provides entropic stabilisation of conformational states (Agarwal et al. 2002) . In addition, there are also slower-(microsecond-millisecond) and larger-scale, thermally activated, transitions. Large-scale conformational changes are usually key events in enzyme regulation.
ENZYME PRODUCTION
In the past, enzymes were isolated primarily from natural sources, and thus a relatively limited number of enzymes were available to the industry (Aehle 2007) . For example, of the hundred or so enzymes being used industrially, over one half are from fungi and yeast and over a third are from bacteria, with the remainder divided between animal (8%) and plant (4%) sources (Panke and Wubbolts 2002 , van Beilen and Li 2002 , Bornscheuer 2005 . Today, with the recent advances of molecular biology and genetic engineering, several expression systems were developed and exploited and used for the commercial production of several therapeutic (Mcgrath 2005) , analytical or industrial enzymes (van Beilen and Li 2002 , Kirk et al. 2002 , Otero and Nielsen 2010 . These systems have not only improved the efficiency, availability and cost with which enzymes can be produced, but they have also improved their quality , Andreadeli et al. 2008 , Kapoli et al. 2008 , Kotzia and Labrou 2009 , Labrou 2010 ).
Enzyme Heterologous Expression
There are two basic steps involved in the assembly of every heterologous expression system: 1. The introduction of the DNA, encoding the gene of interest, into the host cells, which requires: (i) the identification and isolation of the gene of the protein we wish to express, (ii) insertion of the gene into a suitable expression vector and (iii) introduction of the expression vector into the selected cell system that will accommodate the heterologous protein. Polylinker sequence (multiple cloning site (MCS)), promoter (P euk/pro ), terminator (T euk/pro ), selectable marker (prokaryotic and/or eukaryotic -M euk/pro ), and origin of replication (eukaryotic and/or prokaryotic -Ori euk/pro ).
5. Terminator: a strong terminator sequence that ensures that the RNA polymerase disengages and does not continue to transcribe other genes located downstream.
Vectors are usually designed with mixed characteristics for expression in both prokaryotic and eukaryotic host cells (Brondyk 2009, Demain and Vaishnav 2009) . Artificial chromosomes are designed for cloning of very large segments of DNA (100 kb), usually for mapping purposes, and contain host-specific telomeric and centromeric sequences. These sequences permit the proper distribution of the vectors to the daughter cells during cell division and increase chromosome stability (Fig. 7.12 ).
The Choice of Expression System
There are two main categories of expression systems: eukaryotic and prokaryotic (Demain and Vaishnav 2009) . The choice of a suitable expression system involves the consideration of several important factors, such as protein yield, proper folding, post-translational modifications (e.g. phosphorylation, glycosylation), industrial applications of the expressed protein, as well as economic factors. For these reasons, there is no universally applied expression system. A comparison of the most commonly used expression systems is shown in Table 7 .4.
Bacterial Cells
Expression of heterologous proteins in bacteria remains the most extensively used approach for the production of heterologous proteins (Zerbs et al. 2009 ), such as cytokines (Tang et al. 2006 , Rabhi-Essafi et al. 2007 ), membrane proteins (Butzin (Melissis et al. 2006 , Kotzia and Labrou 2007 , Melissis et al. 2007 , Andreadeli et al. 2008 , Wu et al. 2009 , Okino et al. 2010 , antibodies (Kwong and Rader 2009, Xiong et al. 2009 ) and antigens (viral or non-viral; Donayre-Torres et al. 2009 , Liu et al. 2009a , Vahedi et al. 2009 , Ebrahimi et al. 2010 ) at both laboratory and industrial scale (Koehn and Hunt 2009 , Sahdev et al. 2008 , Peti and Page 2007 , Jana and Deb 2005 . Bacteria can be grown inexpensively and genetically manipulated very easily. They can reach very high densities rapidly and express high levels of recombinant proteins, reaching up to 50% of the total protein. However, in many cases, high-level expression correlates with poor quality. Often, the expressed protein is accumulated in the form of insoluble inclusion bodies (misfolded protein aggregate) and additional, sometimes labour-intensive, genetic manipulation or re-solubilisation/refolding steps are required (Burgess 2009 ). Bacterial cells do not possess the eukaryotes' extensive post-translational modification system (such as N-or 
, a serious disadvantage, when posttranslational modifications are essential to the protein's function (Zhang et al. 2004 ). However, they are capable of a surprisingly broad range of covalent modifications such as acetylation, amidation and deamidation, methylation, myristylation, biotinylation and phosphorylation.
Mammalian Cells
Mammalian cells are the ideal candidate for expression hosts (Engelhardt et al. 2009 , Hacker et al. 2009 ) when posttranslational modifications (N-and O-glycosylation, disulfide bond formation) are a critical factor for the efficacy of the expressed protein (Baldi et al. 2007 , Werner et al. 2007 , Durocher and Butler 2009 , Geisse and Fux 2009 , Hacker et al. 2009 ). Despite substantial limitations, such as high cost, low yield, instability of expression and time-consuming, a significant number of proteins (e.g. cytokines; Fox et al. 2004 , Sunley et al. 2008 , Suen et al. 2010 , antibodies (Kim et al. 2008 , Chusainow et al. 2009 ), enzymes (Zhuge et al. 2004 ), viral antigens (Holzer et al. 2003) , blood factors and related proteins (Halabian et al. 2009 , Su et al. 2010 ) are produced in this system because it offers very high product fidelity. However, oligosaccharide processing is species-and cell type-dependent among mammalian cells and differences in the glycosylation pattern have been reported in rodent cell lines and human tissues. The expressed proteins are usually recovered in a bioactive, properly folded form and secreted into the cell culture fluids.
Yeast
Yeast is a widely used expression system with many commercial, medical and basic research applications. The fact that the yeast is the most intensively studied eukaryote at the genetic/molecular level makes it an extremely advantageous expression system (Idiris et al. 2010) . Being unicellular organism, it retains the advantages of bacteria (low cultivation cost, high doubling rate, ease of genetic manipulation, ability to produce heterologous proteins in large-scale quantities) combined with the advantages of higher eukaryotic systems (post-translational modifications). The vast majority of yeast expression work has focused on the well-characterised baker's yeast Saccharomyces cerevisiae (Holz et al. 2003 , Terpitz et al. 2008 , Joubert et al. 2010 ), but a growing number of non-Saccharomyces yeasts are becoming available as hosts for recombinant polypeptide production, such as Hansenula polymorpha, Candida boidinii, Kluyveromyces lactis, Pichia pastoris (Cregg et al. 2000 , Jahic et al. 2006 , van Ooyen et al. 2006 , Yurimoto and Sakai 2009 , Schizosaccharomyces pombe (Alberti et al. 2007 , Ahn et al. 2009 , Takegawa et al. 2009 ), Schwanniomyces occidentalis and Yarrowia lipolytica (Madzak et al. 2004 , Bankar et al. 2009 ). As in bacteria, expression in yeast relies on episomal or integrated multicopy plasmids with tightly regulated gene expression. Despite these advantages, expressed proteins are not always recovered in soluble form and may have to be purified from inclusion bodies. Post-translational modifications in yeast differ greatly from mammalian cells (Jacobs and Callewaert 2009, Hamilton and Gerngross 2007) . This has sometimes proven to be a hindrance when high fidelity of complex carbohydrate modifications found in eukaryotic proteins appears to be important in many medical applications. Yeast cells do not add complex oligosaccharides and are limited to the high-mannose-type carbohydrates. These higher order oligosaccharides are possibly immunogenic and could potentially interfere with the biological activity of the protein.
Filamentous Fungi
Filamentous fungi have been extensively used for studies of eukaryotic gene organisation, regulation and cellular differentiation. Additionally, fungi belonging to the genus Aspergillus and Penicillium are of significant industrial importance because of their applications in food fermentation and their ability to secrete a broad range of biopolymer degrading enzymes and to produce primary (organic acids) and secondary metabolites (antibiotics, vitamins). The extensive genetic knowledge as well as the already well-developed fermentation technology has allowed for the development of heterologous protein expression systems (Nevalainen et al. 2005 , Wang et al. 2005 ) expressing fungal (e.g. glucoamylase (Verdoes et al. 1993) , propyl aminopeptidase (Matsushita-Morita et al. 2009)) or mammalian (e.g. human interleukin-6 (Contreras et al. 1991) , antitrypsin (Chill et al. 2009 ), lactoferrin (Ward et al. 1995) , bovine chymosin (Ward et al. 1990 , Cardoza et al. 2003 ) proteins of industrial and clinical interest using filamentous fungi as hosts. However, the expression levels of mammalian proteins expressed in Aspergillus and Trichoderma species are low compared to homologous proteins. Significant advances in heterologous protein expression have dramatically improved the expression efficiency by fusing the heterologous gene to the 3 -end of a highly expressed homologous gene (mainly glucoamylase). Even so, limitations in protein folding, post-translational modifications, translocation and secretion as well as secretion of extracellular proteases could pose a significant hindrance for the production of bioactive proteins (Gouka et al. 1997 , Nevalainen et al. 2005 , Lubertozzi and Keasling 2009 ).
Insect Cells
Recombinant baculoviruses are widely used as a vector for the expression of recombinant proteins in insect cells (Hitchman et al. 2009 , Jarvis 2009 , Trometer and Falson 2010 , such as enzymes (Zhao et al. 2010) , immunoglobulins (Iizuka et al. 2009 ), viral antigens ) and transcription factors (Fabian et al. 1998 ). The recombinant genes are usually expressed under the control of the polyhedrin or p10 promoter of the Autographa californica nuclear polyhedrosis virus (Ac-NPV) in cultured insect cells of Spodoptera frugiperda (Sf9 cells) or in insect larvae of Lepidopteran species infected with the recombinant baculovirus containing the gene of interest. The polyhedron and p10 genes possess very strong promoters and are highly transcribed during the late stages of the viral cycle. Usually, the recombinant proteins are recovered from the infected insect cells in soluble form and targeted in the proper cellular environment (membrane, nucleus and cytoplasm). Insect cells have many post-translational modification, transport and processing mechanisms found in higher eukaryotic cells (Durocher and Butler 2009) , although their glycosylation efficiency is limited and they are not able to process complex-type oligosaccharides containing fucose, galactose and sialic acid.
Dictyostelium discoideum
Recently, the cellular slime mould Dictyostelium discoideum, a well-studied single-celled organism, has emerged as a promising eukaryotic alternative system (Arya et al. 2008b ) for the expression of recombinant proteins (e.g. human antithrombin III; Dingermann et al. 1991 , Tiltscher and Storr 1993 , Dittrich et al. 1994 ) and enzymes (e.g. phosphodiesterase; Arya et al. 2008a) . Its advantage over other expression systems lies in its extensive post-translational modification system (glycosylation, phosphorylation, acylation), which resembles that of higher eukaryotes (Jung and Williams 1997 , Slade et al. 1997 . It is a simple organism with a haploid genome of 5 × 10 7 bp and a life cycle that alternates between single-celled and multicellular stages. Recombinant proteins are expressed from extrachromosomal plasmids (Dictyostelium discoideum is one of a few eukaryotes that have circular nuclear plasmids) rather than being integrated in the genome (Ahern et al. 1988 ). The nuclear plasmids can be easily genetically manipulated and isolated in a one-step procedure, as in bacteria. This system is ideally suited for the expression of complex glycoproteins and although it retains many of the advantages of the bacterial (low cultivation cost) and mammalian systems (establishment of stable cell lines, glycosylation), the development of this system at an industrial scale is hampered by the relatively low productivity, compared to bacterial systems.
Trypanosomatid Protozoa
A newly developed eukaryotic expression system is based on the protozoan lizard parasites of the Leishmania and Trypanosoma species (Basile and Peticca 2009) . Its gene and protein regulation and editing mechanisms are remarkably similar to those of higher eukaryotes and include the capability of 'mammalianlike' glycosylation. It has a very rapid doubling time and can be grown to high densities in relatively inexpensive medium. The recombinant gene is integrated into the small ribosomal subunit rRNA gene and can be expressed to high levels. Increased expression levels and additional promoter control can be achieved in T7 polymerase-expressing strains. Being a lizard parasite, it is not pathogenic to humans, which makes this system invaluable and highly versatile. Proteins and enzymes of significant interest, such as human tissue plasminogen activator (Soleimani et al. 2007) , EPO (Breitling et al. 2002) , IFNγ (Tobin et al. 1993 ) and IL-2 (La Flamme 1995), have been successfully expressed in this system.
Transgenic Plants
The current protein therapeutics market is clearly an area of enormous interest from a medical and economic point of view. Recent advances in human genomics and biotechnology have made it possible to identify a plethora of potentially important drugs or drug targets. Transgenic technology has provided an alternative, more cost-effective bioproduction system than the previously used (E. coli, yeast, mammalian cells; Larrick and Thomas 2001, Demain and Vaishnav 2009) . The accumulated knowledge on plant genetic manipulation has been recently applied to the development of plant bioproduction systems (Twyman et al. 2005 , Boehm 2007 , Lienard et al. 2007 , Faye and Champey 2008 , Sourrouille et al. 2009 ). Expression in plants could be either constitutive or transient and directed to a specific tissue of the plant (depending on the type of promoter used). Expression of heterologous proteins in plants offers significant advantages, such as low production cost, high biomass production, unlimited supply and ease of expandability. Plants also have high-fidelity expression, folding and post-translational modification mechanisms, which could produce human proteins of substantial structural and functional equivalency compared to proteins from mammalian expression systems (Gomord and Faye 2004, Joshi and Lopez 2005) (Kermode et al. 2007 , Stein et al. 2009 ), are free of potentially hazardous human diseases, viruses or bacterial toxins. However, there is considerable concern regarding the potential hazards of contamination of the natural gene pool by the transgenes and possible additional safety precautions will raise the production cost.
Transgenic Animals
Besides plants, transgenic technology has also been applied to many different species of animals (mice, cows, rabbits, sheep, goats and pigs; Niemann and Kues 2007, Houdebine 2009 ). The DNA containing the gene of interest is microinjected into the pronucleus of a single-cell fertilised zygote and integrated into the genome of the recipient; therefore, it can be faithfully passed on from generation to generation. The gene of interest is coupled with a signal targeting protein expression towards specific tissues, mainly the mammary gland, and the protein can therefore be harvested and purified from milk. The proteins produced by transgenic animals are almost identical to human proteins, greatly expanding the applications of transgenic animals in medicine and biotechnology. Several human protein of pharmaceutical value have been produced in transgenic animals, such as haemoglobin (Swanson 1992, Logan and Martin 1994) , lactoferrin (Han et al. 2008 , Yang et al. 2008 , antithrombin III (Yang et al. 2009 ), protein C (Velander 1992 ) and fibrinogen (Prunkard 1996) , and there is enormous interest for the generation of transgenic tissues suitable for transplantation in humans (only recently overshadowed by primary blastocyte technology (Klimanskaya et al. 2008) ). Despite the initial technological expertise required to produce a transgenic animal, the subsequent operational costs are low and subsequent inbreeding ensures that the ability to produce the transgenic protein will be passed on to its offspring. However, certain safety issues have arisen concerning the potential contamination of transgenically produced proteins by animal viruses or prions, which could possibly be passed on to the human population. Extensive testing required by the FDA substantially raises downstream costs.
Enzyme Purification
Once a suitable enzyme source has been identified, it becomes necessary to design an appropriate purification procedure to isolate the desired protein. The extent of purification required for an enzyme depends on several factors, the most important of which being the degree of enzyme purity required as well as (Berthold and Walter 1994) . Purification of an enzyme usually occurs by a series of independent steps in which the various physicochemical properties of the enzyme of interest are utilised to separate it progressively from other unwanted constituents Clonis 2002, Labrou et al. 2004b ). The characteristics of proteins that are utilised in purification include solubility, ionic charge, molecular size, adsorption properties and binding affinity to other biological molecules. Several methods that exploit differences in these properties are listed in Table 7 .5.
Precipitation methods (usually employing (NH 4 ) 2 SO 4 , polyethyleneglycol or organic solvents) are not very efficient method of purification (Labrou and Clonis 2002) . They typically give only a few fold purification. However, with these methods, the protein may be removed from the growth medium or from cell debris where harmful proteases and other detrimental compounds may affect protein stability. On the other hand, chromatography is a highly selective separation technique (Regnier 1987 , Fausnaugh 1990 . A wide range of chromatographic techniques has been used for enzyme purification: size-exclusion chromatography, ion-exchange, hydroxyapatite, hydrophobic interaction chromatography, reverse-phase chromatography and affinity chromatography (Labrou 2003) . Of these, ion-exchange and affinity chromatography are the most common and probably the most important (Labrou and Clonis 1994) .
Ion-Exchange Chromatography
Ion-exchange resins selectively bind proteins of opposite charge; that is, a negatively charged resin will bind proteins with a net positive charge and vice versa (Fig. 7.13 ). Charged groups are classified according to type (cationic and anionic) and strength (strong or weak); the charge characteristics of strong ion exchange media do not change with pH, whereas with weak ionexchange media they do. The most commonly used charged groups include diethylaminoethyl, a weakly anionic exchanger; carboxymethyl, a weakly cationic exchanger; quaternary ammonium, a strongly anionic exchanger; and methyl sulfonate, a strongly cationic exchanger (Table 7 .6; Levison 2003) . The matrix material for the column is usually formed from beads of carbohydrate polymers, such as agarose, cellulose or dextrans (Levison 2003) .
The technique takes place in five steps (Labrou 2000; Fig. 7.13) : equilibration of the column to pH and ionic strength conditions suitable for target protein binding; protein sample application to the column and reversible adsorption through counter-ion displacement; washing of the unbound contaminating proteins, enzymes, nucleic acids and other compounds; introduction of elution conditions in order to displace bound proteins; and regeneration and re-equilibration of the adsorbent for subsequent purifications. Elution may be achieved either by increasing the salt concentration or by changing the pH of the irrigating buffer. Both methods are used in industry, but raising the salt concentration is by far the most common because it is easier to control (Levison 2003) . Most protein purifications are done on anion exchange columns because most proteins are negatively charged at physiological pH values (pH 6-8).
Affinity Chromatography
Affinity chromatography is potentially the most powerful and selective method for protein purification ( Fig. 7. 14; Clonis 1994, Labrou 2003) . According to the International Union of Pure and Applied Chemistry, affinity chromatography is defined as a liquid chromatographic technique that makes use of a 'biological interaction' for the separation and analysis of specific analytes within a sample. Examples of these interactions include the binding of an enzyme with a substrate/inhibitor or of an antibody with an antigen or in general the interaction of a protein with a binding agent, known as the 'affinity ligand' ( Fig. 7. 14; Labrou 2002 , Labrou et al. 2004b ). The development of an affinity chromatography-based purification step involves the consideration of the following factors: (i) selection of an appropriate ligand and (ii) immobilisation of the ligand onto a suitable support matrix to make an affinity adsorbent. The selection of the immobilised ligand for affinity chromatography is the most challenging aspect of preparing an affinity adsorbent. Certain factors need to be considered when selecting a ligand Clonis 1995, 1996) : (i) the specificity of the ligand for the protein of interest, (ii) the reversibility of the interaction with the protein, (iii) its stability against the biological and chemical operation conditions and (iv) the affinity of the ligand for the protein of interest. The binding site of a protein is often located deep within the molecule and adsorbents prepared by coupling the ligands directly to the support exhibit low binding capacities. This is due to steric interference between the support matrix and the protein's binding site. In these circumstances, a 'spacer arm' is inserted between the matrix and ligand to facilitate effective binding (Fig. 7.14) . A hexyl spacer is usually inserted between ligand and support by substitution of 1,6-diaminohexane (Lowe 2001 ).
The ideal matrix should be hydrophilic, chemically and biologically stable and have sufficient modifiable groups to permit an appropriate degree of substitution with the enzyme. Sepharose is the most commonly used matrix for affinity chromatography on the research scale. Sepharose is a commercially available beaded polymer, which is highly hydrophilic and generally inert to microbiological attack (Labrou and Clonis 2002) . Chemically, it is an agarose (poly-{β-1,3-d-galactose-α-1,4-(3,6-anhydro)-l-galactose}) derivative.
The selection of conditions for an optimum affinity chromatographic purification involves the study of the following factors:
(1) choice of adsorption conditions (e.g. buffer composition, pH, ionic strength) to maximise the conditions required for the formation of strong complex between the ligand and the protein to be purified, (2) choice of washing conditions to desorb non-specifically bound proteins and (3) choice of elution conditions to maximise purification (Labrou and Clonis 1995) . The elution conditions of the bound macromolecule should be both tolerated by the affinity adsorbent and effective in desorbing the biomolecule in good yield and in the native state. Elution of bound proteins is performed in a non-specific or biospecific manner. Non-specific elution usually involves (1) changing the ionic strength (usually by increasing the buffer's molarity or including salt, e.g. KCl or NaCl) and the pH (adsorption generally weakens with increasing pH), (2) altering the polarity of the irrigating buffer by employing, for example ethylene glycol or other organic solvents, if the hydrophobic contribution in the protein-ligand complex is large. Biospecific elution is achieved by inclusion in the equilibration buffer of a suitable ligand, which usually competes with the immobilised ligand for the same binding site on the enzyme/protein (Labrou 2000) . Any competing ligand may be used. For example, substrates, products, cofactors, inhibitors or allosteric effectors are all potential candidates as long as they have higher affinity for the macromolecule than the immobilised ligand. Dye-ligand affinity chromatography represents a powerful affinity-based technique for enzyme and protein purification (Clonis et al. 2000 , Labrou 2002 , Labrou et al. 2004b ). The technique has gained broad popularity due to its simplicity and wide applicability to purify a variety of proteins. The employed dyes as affinity ligands are commercial textile chlorotriazine polysulfonated aromatic molecules, which are usually termed as triazine dyes (Fig. 7.15 ). Such dye-ligands have found wide applications over the past 20 years as general affinity ligands in the research market to purify enzymes, such as oxidoreductases, decarboxylases, glycolytic enzymes, nucleases, hydrolases, lyases, synthetases and transferases (Scopes 1987) . Anthraquinone triazine dyes are probably the most widely used dye-ligands in enzyme and protein purification. Especially the triazine dye Cibacron Blue F3GA (Fig. 7.18 ) has been widely exploited as an affinity chromatographic tool to separate and purify a variety of proteins (Scopes 1987) . With the aim of increasing the specificity of dye-ligands, the biomimetic dye-ligand concept was introduced. According to this concept, new dyes that mimic natural ligands of the targeted proteins are designed by substituting the terminal 2-aminobenzene sulfonate moiety of the dye Cibacron Blue 3GA (CB3GA) for (ή with) a substrate-mimetic moiety (Clonis et al. 2000 , Labrou 2002 , Labrou et al. 2004b ). These biomimetic dyes exhibit increased purification ability and specificity and provide useful tools for designing simple and effective purification protocols. The rapid development of recombinant DNA technology since the early 1980s has changed the emphasis of a classical enzyme purification work. For example, epitope tagging is a recombinant DNA method for inserting a specific protein sequence (affinity tag) into the protein of interest (Terpe 2003) . This allows the expressed tagged protein to be purified by affinity interactions with a ligand that selectively binds to the affinity tag. Examples of affinity tags and their respective ligands used for protein and enzyme purification are shown in Table 7 .7.
ENZYME ENGINEERING
Another extremely promising area of enzyme technology is enzyme engineering. New enzyme structures may be designed and produced in order to improve existing ones or create new activities. Over the past two decades, with the advent of protein engineering, molecular biotechnology has permitted not only the improvement of the properties of these isolated proteins, but also the construction of 'altered versions' of these 'naturally occurring' proteins with novel or 'tailor-made' properties (Ryu 
Tailor-Made Enzymes by Protein Engineering
There are two main intervention approaches for the construction of tailor-made enzymes: rational design and directed evolution (Chen 2001 , Schmidt et al. 2009 Fig. 7.16 ). Rational design takes advantage of knowledge of the three-dimensional structure of the enzyme, as well as structure/function and sequence information to predict, in a 'rational/logical' way, sites on the enzyme that when altered would endow the enzyme with the desired properties (Craik et al. 1985 , Wells et al. 1987 , Carter et al. 1989 , Scrutton et al. 1990 , Cedrone et al. 2000 . Once the crucial amino acids are identified, site-directed mutagenesis is applied and the expressed mutants are screened for the desired properties. It is clear that protein engineering by rational design requires prior knowledge of the 'hot spots' on the enzyme. Directed evolution (or molecular evolution) does not require such prior sequence or three-dimensional structure knowledge, as it usually employs random-mutagenesis protocols to engineer enzymes that are subsequently screened for the desired properties (Tao and Cornish 2002 , Dalby 2003 , Jaeger and Eggert 2004 , Jestin and Kaminski 2004 , Williams et al. 2004 ). However, both approaches require efficient expression as well as sensitive detection systems for the protein of interest (Kotzia et al. 2006) . During the selection process, the mutations that have a positive effect are selected and identified. Usually, repeated rounds of mutagenesis are applied until enzymes with the desired properties are constructed. For example, it took four rounds of random mutagenesis and DNA shuffling of Drosophila melanogaster 2 -deoxynucleoside kinase, followed by FACS analysis, in order to yield an orthogonal ddT kinase with a 6-fold higher activity for the nucleoside analogue and a 20-fold k cat /K m preference for ddT over thymidine, an overall 10,000-fold change in substrate specificity (Liu et al. 2009b) .
Usually, a combination of both methods is employed by the construction of combinatorial libraries of variants, using random mutagenesis on selected (by rational design) areas of the parental 'wild-type' protein (typically, binding surfaces or specific amino acids; Altamirano et al. 2000 , Arnold 2001 , Saven 2002 , Johannes and Zhao 2006 . For example, Park et al. rationally manipulated several active site loops in the ab/ba metallohydrolase scaffold of glyoxalase II through amino acid insertion, deletion, and substitution, and then used directed evolution to introduce random point-mutations to fine-tune the enzyme activity (Park et al. 2006) . The resulting enzyme completely lost its original activity and instead showed β-lactamase activity.
The industrial applications of enzymes as biocatalysts are numerous. Recent advances in genetic engineering have made possible the construction of enzymes with enhanced or altered properties (change of enzyme/cofactor specificity and enantioselectivity, altered thermostability, increased activity) to satisfy the ever-increasing needs of the industry for more efficient catalysts (Bornscheuer and Pohl 2001 , Zaks 2001 , Jaeger and Eggert 2004 , Chaput et al. 2008 , Zeng et al. 2009 ).
Rational Enzyme Design
The rational protein design approach is mainly used for the identification and evaluation of functionally important residues or sites in proteins. Although the protein sequence contains all the information required for protein folding and functions, today's state of technology does not allow for efficient protein design by simple knowledge of the amino acid sequence alone. For example, there are 10 325 ways of rearranging amino acids in a 250-amino-acid-long protein, and prediction of the number of changes required to achieve a desired effect is an obstacle that initially appears impossible. For this reason, a successful rational design cycle requires substantial planning and could be repeated several times before the desired result is achieved. A rational protein design cycle requires the following:
1. Knowledge of the amino acid sequence of the enzyme of interest and availability of an expression system that allows for the production of active enzyme. Isolation and characterisation (annotation) of cDNAs encoding proteins with novel or pre-observed properties has been significantly facilitated by advances in genomics (Schena et al. 1995 , Zweiger and Scott 1997 , Schena et al. 1998 , Carbone 2009 ) and proteomics (Anderson and Anderson 1998 , Steiner and Anderson 2000 , Xie et al. 2009 ) and is increasing rapidly. These cDNA sequences are stored in gene (NCBI) and protein databanks (UniProtKB/Swiss-Prot; Release 57.12 of 15 Dec 09 of UniProtKB/Swiss-Prot contains 513,77 protein sequence entries; Apweiler et al. 2004 , The UniProt Consortium 2008 . However, before the protein design cycle begins, a protein expression system has to be established. Introduction of the cDNA encoding the protein of interest into a suitable expression vector/host cell system is nowadays a standard procedure (see above). 2. Structure/function analysis of the initial protein sequence and determination of the required amino acids changes. As mentioned before, the enzyme engineering process could be repeated several times until the desired result is obtained. Therefore, each cycle ends where the next begins. Although, we cannot accurately predict the conformation of a given protein by knowledge of its amino acid sequence, the amino acid sequence can provide significant information. Initial screening should therefore involve sequence comparison analysis of the original protein sequence to other sequence homologous proteins with potentially similar functions by utilising current bioinformatics tools (Andrade and Sander 1997 , Fenyo and Beavis 2002 , Nam et al. 2009 , Yen et al. 2009 , Zhang et al. 2009a . Areas of conserved or non-conserved amino acids residues can be located within the protein and could possibly provide valuable information, concerning the identification of binding and catalytic residues. Additionally, such methods could also reveal information pertinent to the three-dimensional structure of the protein. 3. Availability of functional assays for identification of changes in the properties of the protein. This is probably the most basic requirement for efficient rational protein design. The expressed protein has to be produced in a bioactive form and characterised for size, function and stability in order to build a baseline comparison platform for the ensuing protein mutants. The functional assays should have the required sensitivity and accuracy to detect the desired changes in the protein's properties. 4. Availability of the three-dimensional structure of the protein or capability of producing a reasonably accurate threedimensional model by computer modelling techniques. The structures of thousands of proteins have been solved by various crystallographic techniques (X-ray diffraction, NMR spectroscopy) and are available in protein structure databanks. Current bioinformatics tools and elaborate molecular modeling software (Wilkins et al. 1999 , Gasteiger et al. 2003 , Guex et al. 2009 ) permit the accurate depiction of these structures and allow the manipulation of the aminoacid sequence. For example, they are able to predict, with significant accuracy, the consequences of a single aminoacid substitution on the conformation, electrostatic or hydrophobic potential of the protein (Guex and Peitsch 1997 , Gasteiger et al. 2003 , Schwede et al. 2003 . Additionally, protein-ligand interactions can, in some cases, be successfully simulated, which is especially important in the identification of functionally important residues in enzyme-cofactor/substrate interactions (Saxena et al. 2009 ). Finally, in allosteric regulation, the induced conformational changes are very difficult to predict. In last few years, studies on the computational modelling of allostery have also began (Kidd et al. 2009 ).
Where the three-dimensional structure of the protein of interest is not available, computer modelling methods (homology modelling, fold recognition using threading and ab initio prediction) allow for the construction of putative models based on known structures of homologous proteins (Schwede et al. 2003 , Kopp and Schwede 2004 , Jaroszewski 2009 , Qu et al. 2009 ). Additionally, comparison with proteins having homologous threedimensional structure or structural motifs could provide clues as to the function of the protein and the location of functionally important sites. Even if the protein of interest shows no homology to any other known protein, current amino acid sequence analysis software could provide putative tertiary structural models. A generalised approach to predict protein structure is shown in Figure 7 .17. 5. Genetic manipulation of the wild-type nucleotide sequence. A combination of previously published experimental literature and sequence/structure analysis information is usually necessary for the identification of functionally important sites in the protein.
Once an adequate three-dimensional structural model of the protein of interest has been constructed, manipulation of the gene of interest is necessary for the construction of mutants. Polymerase chain reaction (PCR) mutagenesis is the basic tool for the genetic manipulation of the nucleotide sequences. The genetically redesigned proteins are engineered by the following: a. Site-directed mutagenesis: alteration of specific amino acid residues. There are a number of experimental approaches designed for this purpose. The basic principle involves the use of synthetic oligonucleotides (oligonucleotide-directed mutagenesis) that are complementary to the cloned gene of interest but contain a single (or sometimes multiple) mismatched base(s) (Balland et al. 1985 , Garvey and Matthews 1990 , Wagner and Benkovic 1990 . The cloned gene is either carried by a single-stranded vector (M13 oligonucleotide-directed mutagenesis) or a plasmid that is later denatured by alkali (plasmid DNA oligonucleotide-directed mutagenesis) or heat (PCR-amplified oligonucleotide-directed mutagenesis) in order for the mismatched oligonucleotide to anneal.
The latter then serves as a primer for DNA synthesis catalysed by externally added DNA polymerase for the creation of a copy of the entire vector, carrying, however, a mutated base. PCR mutagenesis is the most frequently used mutagenesis method (Fig. 7.18 ). For example, substitution of specific amino acid positions by site-directed mutagenesis (S67D/H68D) successfully converted the coenzyme specificity of the short-chain carbonyl reductase from NADP(H) to NAD(H) as well as the product enantioselectivity without disturbing enzyme stability (Zhang et al. 2009 ). In another example, engineering of the maize GSTF1-1 by mutating selected G-site residues resulted in substantial changes in the pH-dependence of kinetic parameters of the enzyme (Labrou et al. 2004a ). Mutation of a key residue in the H-site of the same enzyme (Ile118Phe) led to a fourfold improved specificity of the enzyme towards the herbicide alachlor . So far, substitution of a specific amino acid by another has been limited by the availability of only 20 naturally occurring amino acids. However, it is chemically possible to construct hundreds of designer-made amino acids. Incorporation of these novel protein building blocks could help shed new light into the cellular and protein functions (Wang and Schultz 2002 , Chin et al. 2003 , Deiters et al. 2003 , Arnold 2009 ). 18. PCR oligonucleotide-directed mutagenesis. Two sets of primers are used for the amplification of the double-stranded plasmid DNA. The primers are positioned as shown and only one contains the desired base change. After the initial PCR step, the amplified PCR products are mixed together, denatured and renatured to form, along with the original amplified linear DNA, nicked circular plasmids containing the mutations. Upon transformation into E. coli, the nicked are repaired by host cell enzymes and the circular plasmids can be maintained.
b. Construction of deletion mutants: deletion of specified areas within or at the 5 /3 ends (truncation mutants) of the gene. c. Construction of insertion/fusion mutants: insertion of a functionally/structurally important epitope or fusion to another protein fragment. There are numerous examples of fusion proteins designed to facilitate protein expression and purification, display of proteins on surfaces of cells or phages, cellular localisation, metabolic engineering as well as protein-protein interaction studies (Nixon et al. 1998 ). d. Domain swapping: exchanging of protein domains between homologous or heterologous proteins. For example, exchange of a homologous region between Agrobacterium tumefaciens β-glucosidase (optimum at pH 7.2-7.4 and 60
• C) and Cellvibrio gilvus β-glucosidase (optimum at pH 6.2-6.4 and 35
• C) resulted in a hybrid enzyme with optimal activity at pH 6.6-7.0 and 45-50
• C (Singh et al. 1995) . Also, domain swapping was used to clarify the control of electron transfer in nitric-oxide synthases (Nishida and Ortiz de Montellano 2001) . In another example, domain swapping was observed in the structurally unrelated capsid of a rice yellow mottle virus, a member of the plant icosahedral virus group, where it was demonstrated to increase stability of the viral particle (Qu et al. 2000) .
Although site-directed mutagenesis is widely used, it is not always feasible due to the limited knowledge of protein structure-function relationship and the approximate nature of computer-graphic modelling. In addition, rational design approaches can fail due to unexpected influences exerted by the substitution of one or more amino acid residues (Cherry and Fidantsef 2003, Johannes and Zhao 2006) . Irrational approaches can therefore be preferable alternatives to direct the evolution of enzymes with highly specialised traits (Hibbert and Dalby 2005 , Chatterjee and Yuan 2006 , Johannes and Zhao 2006 .
Directed Enzyme Evolution
Directed evolution by DNA recombination can be described as a mature technology for accelerating protein evolution. Evolution is a powerful algorithm with proven ability to alter enzyme function and especially to 'tune' enzyme properties (Cherry and Fidantsef 2003 , Williams et al. 2004 , Hibbert and Dalby 2005 , Roodveldt et al. 2005 , Chatterjee and Yuan 2006 . The methods of directed evolution use the process of natural selection but in a directed way (Altreuter and Clark 1999 , Kaur and Sharma 2006 , Wong et al. 2006 , Glasner et al. 2007 , Gerlt and Babbitt 2009 , Turner 2009 ). The major step in a typical directed enzyme evolution experiment is first to make a set of mutants and then to find the best variants through a high-throughput selection or screening procedure (Kotzia et al. 2006) . The process can be iterative, so that a 'generation' of molecules can be created in a few weeks or even in a few days, with large numbers of progeny subjected to selective pressures not encountered in nature (Arnold 2001 , Williams et al. 2004 ).
There are many methods to create combinatorial libraries, using directed evolution (Labrou 2010) . Some of these are random mutagenesis using mainly error-prone PCR Madison 1997, Cirino et al. 2003) , DNA shuffling (Stemmer 1994 , Crameri et al. 1998 , Baik et al. 2003 , Bessler et al. 2003 , Dixon et al. 2003 , Wada et al. 2003 , StEP (staggered extension process; Zhao et al. 1998, Aguinaldo and Arnold 2003) , RPR (randompriming in vitro recombination; Shao et al. 1998, Aguinaldo and Arnold 2003) , incremental truncation for the creation of hybrid enzymes (ITCHY; Lutz et al. 2001) , RACHITT (random chimeragenesis on transient templates; Coco et al. 2001 , Coco 2003 , ISM (iterative saturation mutagenesis; Reetz 2007), GSSM (gene site saturation mutagenesis; DeSantis et al. 2003 , Dumon et al. 2008 , PDLGO (protein domain library generation by overlap extension; Gratz and Jose 2008) and DuARCheM (dual approach to random chemical mutagenesis; Mohan and Banerjee 2008) . The most frequently used methods for DNA shuffling are shown in Figure 7 .19.
Currently, directed evolution has gained considerable attention as a commercially important strategy for rapid design of molecules with properties tailored for the biotechnological and pharmaceutical market. Over the past four years, DNA family shuffling has been successfully used to improve enzymes of industrial and therapeutic interest (Kurtzman et al. 2001 , Chiang 2004 , Dai and Copley 2004 , Yuan et al. 2005 . For example, by applying the DNA family shuffling approach, the catalytic properties of cytochrome P450 enzymes were further extended in the chimeric progeny to include a new range of blue colour formations. Therefore, it may be possible to direct the new enzymes towards the production of new dyes (Rosic 2009 ).
IMMOBILISED ENZYMES
The term 'immobilised enzymes' describes enzymes physically confined, localised in a certain region of space or attached on a support matrix (Abdul 1993) . The main advantages of enzyme immobilisation are listed in Table 7 .8.
There are at least four main areas in which immobilised enzymes may find applications, that is industrial, environmental, analytical and chemotherapeutic (Powell 1984 , Liang et al. 2000 . Environmental applications include waste water treatment and the degradation of chemical pollutants of industrial and agricultural origin (Dravis et al. 2001) . Analytical applications include biosensors. Biosensors are analytical devices, which have a biological recognition mechanism (most commonly enzyme) that transduce it into a signal, usually electrical, and can be detected by using a suitable detector (Phadke 1992) . Immobilised enzymes, usually encapsulated, are also being used for their possible chemotherapeutic applications in replacing enzymes that are absent from individuals with certain genetic disorders (DeYoung 1989).
Methods for Immobilisation
There are a number of ways in which an enzyme may be immobilised: adsorption, covalent coupling, cross-linking, matrix entrapment or encapsulation (Podgornik and Tennikova 2002; Fig. 7.20) . These methods will be discussed in the following sections.
Adsorption
Adsorption is the simplest method and involves reversible interactions between the enzyme and the support material ( Fig. 7.20A ). The driving force causing adsorption is usually the formation of several non-covalent bonds such as salt links, van der Waals, hydrophobic and hydrogen bonding (Calleri et al. 2004 ). The methodology is easy to carry out and can be applied to a wide range of support matrices such as alumina, bentonite, cellulose, anion and cation exchange resins, glass, hydroxyapatite, kaolinite, etc. The procedure consists of mixing together the enzyme and a support under suitable conditions of pH, ionic strength, temperature, etc. The most significant advantages of this method are (i) absence of chemicals resulting to a little damage to enzyme and (ii) reversibility, which allows regeneration with fresh enzyme. The main disadvantage of the method is the leakage of the enzyme from the support under many conditions of changes in the pH, temperature and ionic strength. Another disadvantage is the non-specific, adsorption of other proteins or other substances to the support. This may modify the properties of the support or of the immobilised enzyme.
Covalent Coupling
The covalent coupling method is achieved by the formation of a covalent bond between the enzyme and the support ( Fig. 7.20B ). The binding is very strong and therefore little leakage of enzyme from the support occurs (Calleri et al. 2004 ). The bond is formed between reactive electrophile groups present on the support and nucleophile side chains on the surface of the enzyme. These side-chains are usually the amino group (-NH 2 ) of lysine, the imidazole group of histidine, the hydroxyl group (-OH) of serine and threonine, and the sulfydryl group (-SH) of cysteine. Lysine residues are found to be the most generally useful groups for covalent bonding of enzymes to insoluble supports due to their widespread surface exposure and high reactivity, especially in slightly alkaline solutions. It is important that the amino acids essential to the catalytic activity of the enzyme are not involved in the covalent linkage to the support (Dravis et al. 2001) . This may be difficult to achieve, and enzymes immobilised in this fashion generally lose activity upon immobilisation. This problem may be prevented if the enzyme is immobilised in the presence of saturating concentrations of substrate, product or a competitive inhibitor to protect active site residues. This ensures that the active site remains 'unreacted' during the covalent coupling and reduces the occurrence of binding in unproductive conformations.
Various types of beaded supports have been used successfully as for example, natural polymers (e.g. agarose, dextran and cellulose), synthetic polymers (e.g. polyacrylamide, polyacryloyl trihydroxymethylacrylamide, polymethacrylate), inorganic (e.g. silica, metal oxides and controlled pore glass) and microporous flat membrane (Calleri et al. 2004) .
The immobilisation procedure consists of three steps (Calleri et al. 2004 ): (i) activation of the support, (ii) coupling of ligand and (iii) blocking of residual functional groups in the matrix. The choice of coupling chemistry depends on the enzyme to be immobilised and its stability. A number of methods are available in the literature for efficient immobilisation of enzyme through a chosen particular functional side chain's group by employing glutaraldehyde, oxirane, cyanogen bromide, 1,1-carbonyldiimidazole, cyanuric chloride, trialkoxysilane to derivatise glass, etc. Some of them are illustrated in Figure 7 .21.
Cross-linking
This type of immobilisation is achieved by cross-linking the enzymes to each other to form complex structures as shown in Figure 7 .20C. It is therefore a support-free method and less costly than covalent linkage. Methods of cross-linking involve covalent bond formation between the enzymes using bi-or multifunctional reagent. Cross-linking is frequently carried out using glutaraldehyde, which is of low cost and available in industrial quantities. To minimise close proximity problems associated with the cross-linking of a single enzyme, albumin and gelatin are usually used to provide additional protein molecules as spacers (Podgornik and Tennikova 2002) .
Entrapment and Encapsulation
In the immobilisation by entrapment, the enzyme molecules are free in solution, but restricted in movement by the lattice structure of the gel ( Fig. 7.20D ; Balabushevich et al. 2004 ). The entrapment method of immobilisation is based on the localisation of an enzyme within the lattice of a polymer matrix or membrane (Podgornik and Tennikova 2002) . It is done in such a way as to retain protein while allowing penetration of substrate. Entrapment can be achieved by mixing an enzyme with chemical monomers that are then polymerised to form a crosslinked polymeric network, trapping the enzyme in the interstitial spaces of lattice. Many materials have been used, such as alginate, agarose, gelatin, polystyrene and polyacrylamide. As an example of this latter method, the enzymes' surface lysine residues may be derivatised by reaction with acryloyl chloride (CH 2 = CH-CO-Cl) to give the acryloyl amides. This product may then be copolymerised and cross-linked with acrylamide (CH 2 = CH-CO-NH 2 ) and bisacrylamide (H 2 N-CO-CH = CH-CH = CH-CO-NH 2 ) to form a gel.
Encapsulation of enzymes can be achieved by enveloping the biological components within various forms of semipermeable membranes as shown in Figure 7 .20E. Encapsulation is most frequently carried out using nylon and cellulose nitrate to construct microcapsules varying from 10 to 100 μM. In general, entrapment methods have found more application on the immobilisation of cells.
New Approaches for Oriented Enzyme Immobilisation: The Development of Enzyme Arrays
With the completion of several genome projects, attention has turned to the elucidation of functional activities of the encoded proteins. Because of the enormous number of newly discovered open reading frames, progress in the analysis of the corresponding proteins depends on the ability to perform characterisation in a parallel and high throughput format (Cahill and Nordhoff 2003) . This typically involves construction of protein arrays based on recombinant proteins. Such arrays are then analysed for their enzymatic activities and the ability to interact with other proteins or small molecules, etc. The development of enzyme array technology is hindered by the complexity of protein molecules. The tremendous variability in the nature of enzymes and consequently in the requirement for their detection and identification makes the development of protein chips a particularly challenging task. Additionally, enzyme molecules must be immobilised on a matrix in a way that they preserve their native structures and are accessible to their targets (Cutler 2003) . The immobilisation chemistry must be compatible with preserving enzyme molecules in native states. This requires good control of local molecular environments of the immobilised enzyme molecule (Yeo et al. 2004 ). There is one major barrier in enzyme microarray development: the immobilisation chemistry has to be such that it preserves the enzyme in native state and with optimal orientation for substrate interaction. This problem may be solved by the recently developed in vitro protein ligation methodology. Central to this method is the ability of certain protein domains (inteins) to excise themselves from a precursor protein (Lue et al. 2004) . In a simplified intein expression system, a thiol reagent induces cleavage of the intein-extein bond, leaving a reactive thioester group on the C-terminus of the protein of interest. This group can then be used to couple essentially any polypeptide with an N-terminal cysteine to the thioester tagged protein by restoring the peptide bond. In another methodology, optimal orientation is based on the unique ability of protein prenyl-transferases to recognise short but highly specific C-terminal protein sequences (Cys-A-A-X-), as shown in Figure 7 .22. The enzyme accepts a spectrum of phosphoisoprenoid analogues while displaying a very strict specificity for the protein substrate. This feature is explored for protein derivatisation. Several types of pyrophosphates (biotin analogues, photoreactive aside and benzophenone analogues; Fig. 7 .22) can be covalently attached to the protein tagged with the Cys-A-A-X motif. After modification, the protein can be immobilised directly either reversibly through biotin-avidin interaction on avidin modified support or covalently through the photoreactive group on several supports. 
ENZYME UTILISATION IN INDUSTRY
Enzymes offer potential for many exciting applications in industry. Some important industrial enzymes and their sources are listed in Table 7 .9. In addition to the industrial enzymes listed above, a number of enzyme products have been approved for therapeutic use. Examples include tissue plasminogen activator and streptokinase for cardiovascular disease, adenosine deaminase for the rare severe combined immunodeficiency disease, β-glucocerebrosidase for Type 1 Gaucher disease, l-asparaginase for the treatment of acute lymphoblastic leukemia, DNAse for the treatment of cystic fibrosis and neuraminidase which is being targeted for the treatment of influenza (Cutler 2003) .
There are also thousands of enzyme products used in small amounts for research and development in routine laboratory practice and others that are used in clinical laboratory assays. This group also includes a number of DNA-and RNA-modifying enzymes (DNA and RNA polymerase, DNA ligase, restriction endonucleases, reverse transcriptase, etc.), which led to the development of molecular biology methods and were a foundation for the biotechnology industry (Yeo et al. 2004 ). The clever application of one thermostable DNA polymerase led to the PCR and this has since blossomed into numerous clinical, forensic and academic embodiments. Along with the commercial success of these enzyme products, other enzyme products are currently in commercial development.
Another important field of application of enzymes is in metabolic engineering. Metabolic engineering is a new approach involving the targeted and purposeful manipulation of the metabolic pathways of an organism, aiming at improving the quality and yields of commercially important compounds. It typically involves alteration of cellular activities by manipulation of the enzymatic functions of the cell using recombinant DNA and other genetic techniques. For example, the combination of rational pathway engineering and directed evolution has been successfully applied to optimise the pathways for the production of isoprenoids such as carotenoids (Schmidt-Dannert et al. 2000, Umeno and Arnold 2004) . 
ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND BIOCHEMICAL INDIVIDUALITY
The term xenobiotic metabolism refers to the set of metabolic pathways that chemically modify xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as drugs and poisons. The term biochemical individuality of xenobiotic metabolism refers to variability in xenobiotic metabolism and drug responsiveness among different people. Biochemical individuality is a significant factor that can improve public health, drug therapy, nutrition and health impacts such as cancer, diabetes 2 and cardiovascular disease. Most xenobiotics are lipophilic and able to bind to lipid membranes and be transported in the blood (Hodgson 2004) . The enzymes that are involved in xenobiotic metabolism (Table 7 .10) comprise one of the first defense mechanism against environmental carcinogens and xenobiotic compounds (Zhang et al. 2009a) . Xenobiotic metabolism follows mainly three phases (I, II, III). In Phase I, the original compound obtain increased hydrophilicity and constitute an adequate substrate for phase II enzymes, by the introduction of a polar reactive group (-OH, -NH 2 , -SH or -COOH). In Phase II, the products of Phase I can be conjugated to substrates such as GSH, which result in a significant increase of water solubility of xenobiotic, promoting its excretion (Hodgson 2004) . The ATP-dependent transporters that facilitate the movement of the polar conjugates (by phase I and II) across biological membranes and their excretion from the cell constitute Phase III proteins (Josephy and Mannervik 2006) . In general, the enzymes that are involved in xenobiotic metabolism are genetically polymorphic, affecting the individual delicacy to environmental pollutants (Zhang et al. 2009a ).
Phase I
Human cytochrome P450, is one of the most important enzymes that takes part in xenobiotic metabolism; therefore, its genetic polymorphisms have been studied in depth. For example, P450 2A6 (CYP2A6) catalyses nicotine oxidation, and it has been found to have inter-individual and inter-ethnic variability. Genetic polymorphisms of this gene impact smoking behaviour (Xu et al. 2002) . Another example of genetic polymorphism's impact of this enzyme came from Siraj et al., who suggested that CYP1A1 phenotype AA showed association with increased risk of developing papillary thyroid cancer in Middle Eastern population (Siraj et al. 2008) . Another studied genetic polymorphic enzyme is superoxide dismutase-2 (SOD). The heterozygosity 9Val-allele of MnSOD is associated with a higher risk and severity of orofaciolingual dyskinesias (TDof) in Russian psychiatric inpatients from Siberia (Al Hadithy et al. 2010 ). In addition, there are several studies that have reported and showed that the 9Val/9Val genotype confer great susceptibility to tardive dyskinesia (Zhang et al. 2003 , Akyol et al. 2005 , Galecki et al. 2006 , Hitzeroth et al. 2007 ). In addition, human MnSOD gene encoding alanine (A) or valine at codon 16 (Shimoda-Matsubayashi et al. 1996) can be a risk factor for several malignancies (Iguchi et al. 2009 ).
Phase II
Polymorphisms of human UGT correlate with diseases and side effects of drugs, for example the isoform UGT1A1 is associated with diseases of bilirubin metabolism (Hodgson 2004) . N-Acetyltransferases (NAT) are important enzymes that participate in metabolic activation of carcinogenic aromatic and heterocyclic amines that are present in cigarette smoke (Wang et al. 1999 ). An association was found between smokers with MnSOD AA genotype and prostate cancer risk, especially in case of rapid NAT1 subjects (Iguchi et al. 2009 ). Tamini et al. found that the AA genotype of MnSOD in women smokers have an elevated risk for breast cancer (Tamini et al. 2004) .
Tobacco smoke (Lioy and Greenberg 1990) as well as smoked foods, cereals, leafy green vegetables and fossil fuels combustion by-products (Waldman et al. 1991) are the sources of exposure to polycyclic aromatic hydrocarbons (PAHs). PAHs have been considered as potential carcinogens for human (Shimada 2006) . According to McCarty et al., the lack of dose-response relationship of PAHs and breast cancer may be due to genetic differences in metabolic activation and detoxification of PAHs (McCarty et al. 2009 ).
Phase III
The proteins of phase III are membrane transporters. These proteins seem to be significantly implicated in the absorption, distribution and discard of drugs (Rommel and Richard 2002) . There are genetic polymorphisms of drug transporters, which appear to have clinical impact and have been detected in multiple clinical and in vitro studies (Maeda and Sugiyama 2008) .
